Ropes & Gray advised Verastem, while Covington advised the underwriters in the offering. Verastem, Inc. announced its $85 million public offering of common stock and pre-funded warrants....
Verastem’s $85 Million Public Offering
SI-BONE’s $83.05 Million Common Stock Offering
Cooley advised SI-BONE on the offering, and Latham & Watkins advised the underwriters involved. SI-BONE, Inc. has announced the pricing of its underwritten public offering of 3,775,000...
Vaxcyte’s $500 Million Public Offering
Cooley advises Vaxcyte on the offering, and Latham & Watkins advises the underwriters. Vaxcyte, Inc. (Nasdaq: PCVX) has announced the pricing of an underwritten public offering...
Longboard Pharmaceuticals’ $20 Million Common Stock Offering
Cooley advised Longboard Pharmaceuticals on the offering, and Latham & Watkins advised the underwriters involved. Longboard Pharmaceuticals, Inc. announced the pricing of its previously announced underwritten public...
Roivant Sciences’ $230 Million Common Shares Offering
Davis Polk & Wardwell represented Roivant Sciences, while Latham & Watkins represented the underwriters in the offering. Roivant Sciences (Nasdaq: ROIV) has announced its $230 million...
RAPT Therapeutics’ $75 Million Common Stock Offering
Cooley advised RAPT Therapeutics, while Davis Polk advised the joint book-running managers in the offering. RAPT Therapeutics, Inc. executed a $75 million SEC-registered follow-on offering of 4,054,055...
Roivant Sciences’ $150 Million Equity Offering
Davis Polk advised Roivant Sciences Ltd. in the deal, while Covington represented the underwriter, Cantor Fitzgerald. Roivant Sciences Ltd. announced its debut SEC-registered offering of 30,000,000...
Marinus Pharmaceuticals’ $60 Million Public Offering
Covington represented the underwriters on the deal. Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders,...
Vaxcyte’s $690 Million Public Offering
Cooley advised Vaxcyte, while Latham & Watkins represented the underwriters on the offering. Vaxcyte, a clinical-stage vaccine innovation company, announced its underwritten public offering of common stock and...
Denali Therapeutics’ $316 Million Public Offering
Wilson Sonsini Goodrich & Rosati advised Denali Therapeutics on the deal, while Davis Polk advised the representatives of the several underwriters. Denali Therapeutics, a biopharmaceutical company...
Cantor Fitzgerald and Howard Lutnick’s $400 Million Stockholder Derivative Suit
Latham successfully represented Cantor Fitzgerald, L.P., CF Group Management Inc. (together with Cantor Fitzgerald, L.P., Cantor), and Howard Lutnick in the lawsuit. On August 19, 2022,...
Village Farms International’s $50 Million Equity Offering Sales Agreement
Miller Thomson acted as Canadian counsel to the Sales Agents. Village Farms International, Inc. (NASDAQ:VFF) announced that it has entered into a Controlled Equity Offering Sales Agreement...